ClinicalTrials.gg
Not yet recruitingNCT07410767Updated Feb 18, 2026

Advanced Endoscopic Resections for Rectal Neoplasms

An observational study in Rectal Cancer, Rectal Adenocarcinoma and Rectal Adenoma, sponsored by Jagiellonian University. Not yet recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Jagiellonian University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Rectal Neoplasms with a site in Poland — 4 open to participants now, 8 under way, 3 of them phase 3. Rectal Neoplasms · Poland.

Started
2026
with 1 other
Observational
3 of 31
2 open now
Registered
29th of 31
by date
Lead sponsor
5 of 31
Jagiellonian University

Among the 31 studies in Rectal Neoplasms with a site in Poland, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 29th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

4 of the 31 studies in Rectal Neoplasms with a site in Poland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Rectal Neoplasms with a site in Poland, or all of them as a file.
02

Study summary

This study evaluates how advanced endoscopic resection techniques affect treatment outcomes in adults with rectal cancer.

Rectal cancer has traditionally been treated with standard abdominal surgery. Newer endoscopic techniques allow removal of selected early tumors and may reduce treatment-related complications. However, their effectiveness and safety in tumors with deeper invasion are not yet fully established.

This multicenter retrospective observational study uses existing medical records from adults who underwent endoscopic or surgical resection of rectal tumors between 2015 and 2025. Researchers will analyze anonymized information on procedures performed and treatment outcomes to assess the safety and effectiveness of advanced endoscopic approaches.

The results of this study may help guide treatment selection and improve care for people with rectal cancer.

03

Conditions studied

  • Rectal Cancer
  • Rectal Adenocarcinoma
  • Rectal Adenoma
  • Rectal Neuroendocrine Neoplasm
  • Recurrent Rectal Adenocarcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with rectal neoplasms treated with advanced endoscopic resection in a tertiary center.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with rectal neoplasms treated by advanced endoscopic resection

Exclusion criteria

Exclusion Criteria:

  • hybrid resection performed
  • full-thickness resection performed
  • essential procedural or outcome data were unavailable
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • ESD

    Patients who underwent endoscopic submucosal dissection for rectal neoplasm

    Procedure: Endoscopic submucosal dissection

  • EID

    Patients who underwent endoscopic intermuscular dissection for rectal neoplasm

    Procedure: Endoscopic intramuscular dissection

Interventions

  • ProcedureEndoscopic submucosal dissection

    Endoscopic submucosal dissection is an advanced endoscopic technique used to remove rectal tumors in one piece through the endoscope. A circumferential incision is then made in the mucosa, followed by careful dissection within the submucosal layer until the lesion is completely removed. This technique enables precise pathological assessment of tumor margins and depth of invasion and is typically used for lesions suspected to have superficial submucosal invasion without clear evidence of lymph node involvement. The procedure is performed using standard therapeutic endoscopic equipment and electrosurgical devices.

  • ProcedureEndoscopic intramuscular dissection

    Endoscopic intermuscular dissection is an advanced endoscopic resection technique designed for rectal tumors with suspected deeper submucosal invasion. Following mucosal incision, the dissection is intentionally performed in the plane between the inner circular and outer longitudinal muscle layers of the rectal wall. This allows deeper en bloc tumor removal compared with conventional endoscopic submucosal dissection. The goal of this technique is to achieve complete resection while potentially avoiding radical surgery in selected patients. The procedure is performed endoscopically using specialized dissection knives and electrosurgical systems and requires advanced operator expertise.

06

What researchers measure

Primary outcomes

  1. Major intraprocedural bleeding rate

    Bleeding occurring during the procedure that required advanced endoscopic hemostatic interventions beyond standard coagulation with the tip of the knife of coagulation forceps, resulted in hemodynamic instability, caused a significant prolongation of the procedure over 15 minutes (based on video), or led to procedure interruption or conversion

    Time frame: During the procedure

  2. Intraprocedural perforation rate

    Full-thickness defect of the gastrointestinal wall identified during the procedure, evidenced by direct visualization of extraluminal structures (mesorectum or peritoneal cavity), or confirmed by the presence of free air on imaging performed immediately after the procedure.

    Time frame: During the procedure

  3. Delayed bleeding rate

    Symptomatic bleeding including hematemesis, melena, or a hemoglobin decrease of more than 2 g/dL.

    Time frame: Within 28 days after the procedure

  4. Delayed perforation rate

    Clinical signs of peritonitis accompanied by radiological evidence of free intraperitoneal air.

    Time frame: Within 14 days after the procedure

  5. Post-coagulation syndrome rate

    The occurrence of localized abdominal pain or peritoneal irritation signs after EID, accompanied by inflammatory response (elevated white blood cell count or C-reactive protein), in the absence of radiological or endoscopic evidence of perforation.

    Time frame: Within 28 days following the procedure

  6. The need for emergency interventions

    Any unplanned therapeutic intervention related to the index procedure during hospitalization or follow-up, including repeat endoscopy, endoscopic or radiological intervention, blood transfusion, or surgical treatment. Planned surveillance procedures were not considered additional interventions.

    Time frame: Within 30 days after the procedure

  7. Procedure-related mortality rate

    Number of deaths occurring within 30 days of the index procedure that was directly attributable to the procedure or to procedure-related complications. Deaths unrelated to the procedure were reported but not considered procedure-related mortality.

    Time frame: Within 30 days after the procedure

Secondary outcomes

  1. En bloc resection rate

    The rate of lesions removed in a single specimen, enabling accurate macroscopic and histological assessment as reported by an endoscopist in a procedure protocol.

    Time frame: Intraprocedural

  2. Complete resection rate

    The rate of lesions resected completely according to the pathological examination of the resected specimen.

    Time frame: Within 30 days after the procedure

  3. Procedure time

    Procedure time was evaluated on the procedure video and defined as the interval from the insertion of the scope to its final withdrawal measured in minutes; anesthesia-related time was not included.

    Time frame: Intraprocedural

  4. Length of hospital stay

    The number of days from the day of the procedure (day 0) to the day of hospital discharge.

    Time frame: Within 30 days after the procedure

  5. The need for additional treatment

    The number of patients who required completion surgery or adjuvant (chemo)radiotherapy.

    Time frame: Within 12 months after the procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Permission for data sharing was not included in the bioethics committee approval.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Apr 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2026
First posted
Feb 13, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Apr 30, 2026
CompletionEst.
Apr 30, 2026
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07410767
Responsible party
Zofia Orzeszko (MD, Consultant General Surgeon, Jagiellonian University) — Principal investigator
First posted
Feb 13, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Apr 30, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Feb 18, 2026

Study contacts

Zofia Orzeszko, MD
Contact
zofia.orzeszko@uj.edu.pl
+123797145

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion